Revvity reported $2.91B of revenue over the trailing twelve months, +4.1% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $2.91B (to Q2 2026). Net Income: $238M, trailing twelve months to Q2 2026. Free Cash Flow: $558M, trailing twelve months to Q2 2026. Op Margin: 12%, trailing twelve months to Q2 2026.

RVTYRevvity

HealthcareUSD

$126.37

$82.2652 weeks$126.37

RVTY as reported

Revvity reported $2.91B of revenue over the trailing twelve months, +4.1% on the year before. 11 reported series are charted on this page, each one as filed.

$2.91B

Revenue, trailing twelve months · to Q2 2026 · +4.1% against the twelve months before

Net Income: $238M
Net Income · −17% year on year · trailing twelve months to Q2 2026
Free Cash Flow: $558M
Free Cash Flow · +11% year on year · trailing twelve months to Q2 2026
Op Margin: 12%
Op Margin · trailing twelve months to Q2 2026

Every series Ryufin has for RVTY, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$2.91B	+4.1%	Q2 2026
Net Income	$238M	−17%	Q2 2026
EPS	$2.09	−11%	Q2 2026
Gross Margin	57%	n/a	Q3 2023 · 11 quarters behind
Op Margin	12%	n/a	Q2 2026
Net Margin	8.1%	n/a	Q2 2026
ROE	3.3%	n/a	Q2 2026
ROA	2.0%	n/a	Q2 2026
ROIC	3.0%	n/a	Q2 2026
Free Cash Flow	$558M	+11%	Q2 2026
P/E	60.5	n/a	today